Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Corvus Pharmaceuticals, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Nasal swab test positive by reverse transcriptase PCR for SARS CoV-2 within past 7 days, and onset of COVID-19 symptoms no more than 10 days prior to the positive test
Hospitalized and have stable mild to moderate symptoms of COVID-19
Blood oxygen saturation of a minimum of 92% on either no oxygen or up to 5L/min supplemental oxygen
Patients with cancer must be in remission or have stable, controlled disease and may be actively receiving drugs or biologics not deemed by the investigator to likely affect immune response.
Women must not be of child bearing potential or agree to use contraceptive guidance for 6 weeks
You may not be if
Patients receiving previous invasive mechanical ventilation or non-invasive ventilation (CPAP, BiPAP) for COVID-19 illness
Patients hospitalized \>7 days prior to receiving study intervention
Other diseases or conditions that are not controlled
On drugs or biologics that are immunosuppressive, cytotoxic or immunomodulatory
Patients with autoimmune disease must be controlled on non immunosuppressive or immune modifying agents
Have received cytotoxic, immunosuppressive or immunomodulatory agents within past 3 months (other than for treatment of COVID-19).
Patients receiving experimental therapies that are immunosuppressive
Patients receiving non-immuno-suppressive experimental therapies within 7 days prior to receiving CPI-006
Patients receiving convalescent plasma within 24 hours prior to receiving CPI-006
Patients receiving experimental anti-SARS CoV-2 monoclonal antibodies within past 30 days
Clareo Health | Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients
